News und Analysen
Why Exelixis, Inc. Could Be a Gold Mine for Growth Investors
Exelixis, Inc. (NASDAQ: EXEL) has already delivered big gains this year, but there could be a few untapped veins in this biotech gold mine. We'll need to tread lightly because a great deal of....
Why 2017 Was a Year to Remember for Intuitive Surgical, Inc.
Stocks of companies with solid business models and products that meet needs tend to perform well over the long run. Intuitive Surgical, Inc. (NASDAQ: ISRG) is a good example. The robotic surgical....
Why 2017 Was a Year to Remember for Intuitive Surgical, Inc.
Stocks of companies with solid business models and products that meet needs tend to perform well over the long run. Intuitive Surgical, Inc. (NASDAQ: ISRG) is a good example. The robotic surgical....
Why 2017 Was a Year to Remember for Intuitive Surgical, Inc.
Stocks of companies with solid business models and products that meet needs tend to perform well over the long run. Intuitive Surgical, Inc. (NASDAQ: ISRG) is a good example. The robotic surgical....
Exelixis' Cabometyx Takes Aim at Sutent in Kidney Cancer
After reporting in 2016 that its second-line kidney cancer drug, Cabometyx, outperformed Pfizer Inc.'s (NYSE: PFE) top-selling Sutent in first-line advanced kidney cancer patients, Exelixis....
3 Top Generic Drug Stocks to Consider Buying Now
Brand-name drugs tend to capture all the headlines, but did you know that nine out of every 10 prescriptions filled in the U.S. each year are generic? When added together, Americans spend spent....
3 Top Generic Drug Stocks to Consider Buying Now
Brand-name drugs tend to capture all the headlines, but did you know that nine out of every 10 prescriptions filled in the U.S. each year are generic? When added together, Americans spend spent....
Portola Pharmaceuticals Gets a Surprise Present From the FDA
The FDA approved Portola Pharmaceuticals' (NASDAQ: PTLA) first commercial drug, Bevyxxa, in June, but changes to its manufacturing process resulted in the filing of a prior approval supplement....
What to Expect From Corbus Pharmaceuticals in 2018
For a brief few weeks in 2017, it looked like Corbus Pharmaceuticals (NASDAQ: CRBP) could be making another big play after a terrific performance in the previous year. The stock gained more than....
What to Expect From Celgene Corporation in 2018
After two years of lackluster performances, Celgene Corporation (NASDAQ: CELG) appeared to be on a roll in 2017. Then the bottom fell out.In October, the big biotech stock gave up all of its....
Aerie Pharmaceuticals Nabs FDA OK for Glaucoma Drug
Aerie Pharmaceuticals' (NASDAQ: AERI) Rhopressa has secured Food and Drug Administration approval for use as an alternative to beta blockers in glaucoma patients that fail to respond adequately to....
The FDA Just Approved a Game-Changing Therapy for Blindness
A decision on Spark Therapeutics' (NASDAQ: ONCE) vision-restoring gene therapy, Luxturna, was expected next month, but the Food and Drug Administration decided an early OK was warranted following....
New Gene Therapies Could Change Hemophilia Forever
At last week's American Society of Hemophilia conference, Spark Therapeutics (NASDAQ: ONCE) and BioMarin (NASDAQ: BMRN) presented promising data for gene therapy drugs that could change the way....
New Gene Therapies Could Change Hemophilia Forever
At last week's American Society of Hemophilia conference, Spark Therapeutics (NASDAQ: ONCE) and BioMarin (NASDAQ: BMRN) presented promising data for gene therapy drugs that could change the way....
3 Top Pharmaceutical Dividend Stocks to Buy Now
Income investors have favored the pharmaceutical sector for decades. That makes sense since drugs tend to enjoy high margins and are needed in good times and bad. These factors allow pharma....
Why Riot Blockchain Stock Is Soaring... Again
Shares of Riot Blockchain (NASDAQ: RIOT) are up 15% as of 12:00 p.m. EST after the company announced it raised a fresh round of capital by selling stock and warrants in a private placement. A....
Celgene Stock Up Huge On Exciting CAR-T News
At the recent annual American Society of Hematology (ASH) conference, Celgene (NASDAQ: CELG) reported trial results for the multiple myeloma CAR-T drug it's making with bluebird bio (NASDAQ:....
Celgene Shareholders Excited by CAR-T News
At the recent annual American Society of Hematology (ASH) conference, Celgene (NASDAQ: CELG) reported trial results for the multiple myeloma CAR-T drug it's making with bluebird bio (NASDAQ:....
Bitcoin Stocks: It's the Name That Counts
As the tech sector boomed during the late 1990s, shrewd companies quickly figured out how to send their share prices soaring. If they renamed their company to something that ended with ".com,"....
Why Novavax Stock Is Tumbling Today
Shares of the clinical-stage biotech Novavax (NASDAQ: NVAX) fell by as much as 18.2% in pre-marketing trading this morning. What's going on? Investors -- or more likely day traders -- appear to be....
This Possible Dog of the Dow Just Got Even More Interesting
If you invest in the Dogs of the Dow every year, you could end up buying Pfizer (NYSE: PFE) on Jan. 1. The strategy calls for buying the top 10 highest dividend-yielding stocks in the Dow Jones....
This Possible Dog of the Dow Just Got Even More Interesting
If you invest in the Dogs of the Dow every year, you could end up buying Pfizer (NYSE: PFE) on Jan. 1. The strategy calls for buying the top 10 highest dividend-yielding stocks in the Dow Jones....
How Safe Is Medtronic's Dividend?
Advances in medicine have come at a fast and furious pace in recent decades. New pharmaceuticals and biotechnology solutions have made patients healthier, and medical devices like the ones that....
Is Aurinia Pharmaceuticals a Buy?
There's good news and bad news for Aurinia Pharmaceuticals (NASDAQ: AUPH) shareholders. Let's start with the good news. The company has had a fantastic 2017, with its stock price soaring more than....
The Top 3 Dividend Aristocrats to Watch in 2018
Income investors rely on the Dividend Aristocrats to provide them with reliable, growing dividend income. These stocks have all raised the amount they pay in dividends year in and year out for at....